Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Nicotine Replacement Therapy for Smoking Cessation in Schizophrenia

This study has been completed.
Information provided by:
North Suffolk Mental Health Association Identifier:
First received: April 28, 2006
Last updated: May 15, 2009
Last verified: May 2009

This proposal seeks to evaluate a pilot smoking cessation treatment program that will combine nicotine replacement therapy with or without bupropion sustained-release (SR) with cognitive behavioral therapy for smoking cessation in patients with major mental illness.

Condition Intervention Phase
Schizoaffective Disorder
Drug: bupropion, transdermal nicotine patch
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: Nicotine Replacement Therapy Added to Cognitive Behavioral Therapy for Smoking Cessation in Patients With Major Mental Illness

Resource links provided by NLM:

Further study details as provided by North Suffolk Mental Health Association:

Primary Outcome Measures:
  • improvement in smoking cessation and smoking reduction rates when compared to NRT alone added to CBT in patients with schizophrenia and schizoaffective disorder

Secondary Outcome Measures:
  • improvement in negative symptoms, depression and impulsivity when compared to NRT alone in patients with schizophrenia and schizoaffective disorder who quit smoking

Estimated Enrollment: 100
Study Start Date: July 2001
Estimated Study Completion Date: December 2005
  Show Detailed Description


Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria

  1. Women and men aged 18-70 with a diagnosis of schizophrenia or schizoaffective disorder (depressed type or bipolar type) by structured diagnostic interview or chart review
  2. Clinically stable on a stable dose of antipsychotic medication for at least one month, no current active suicidal ideation
  3. Expired air CO > 9 ppm and self report of smoking >1/2 pack per day of cigarettes
  4. Willing to set a smoking quit date within one month of beginning treatment
  5. Not treated with investigational medication in the past 30 days
  6. Competent to provide informed consent or able to provide assent with legal guardian informed consent
  7. Meet DSM-IV criteria for Nicotine Dependence, as determined with the Fagerstrom Nicotine Tolerance Questionnaire (FTQ) (Fagerstrom, 1978)
  8. Compliant with last 3 clinic visits

Exclusion Criteria

  1. Diagnosis of dementia, neurodegenerative disease, current anorexia/bulimia nervosa, current substance abuse or dependence disorders, including alcohol, active within the last 3 months or any Axis I DSM-IV diagnosis other than schizophrenia or schizoaffective disorder
  2. Severe or unstable angina; myocardial infarction in the past 2 weeks; untreated peptic ulcer; life-threatening arrhythmia; poorly controlled insulin dependent diabetes mellitus, uncontrolled hypertension, cerebrovascular event within six months; or allergy to a nicotine patch. Serious illness including cardiovascular, hepatic, renal, respiratory, endocrine, neurologic, or hematologic disease that is not stabilized such that hospitalization for treatment of that illness is likely within the next two months
  3. Patients who, in the investigator's opinion, pose a current severe homicide or suicide risk
  4. Subjects with a history of skin diseases (e.g., psoriasis), skin allergies, or strong reactions to topical preparations, medical dressings or tapes
  5. Current use of topical medications
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00320723

United States, Massachusetts
Freedom Trail Clinic
Boston, Massachusetts, United States, 02114
Sponsors and Collaborators
North Suffolk Mental Health Association
Principal Investigator: A Eden Evins, MD, MPH North Suffolk Mental Health Association
  More Information

No publications provided

Responsible Party: A Eden Evins, MD, MPH, Massachusetts General Hospital Identifier: NCT00320723     History of Changes
Other Study ID Numbers: DMH CORRC 20-01
Study First Received: April 28, 2006
Last Updated: May 15, 2009
Health Authority: United States: Institutional Review Board

Keywords provided by North Suffolk Mental Health Association:
smoking cessation
nicotine replacement therapy
cognitive behavioral therapy

Additional relevant MeSH terms:
Psychotic Disorders
Mental Disorders
Schizophrenia and Disorders with Psychotic Features
Antidepressive Agents
Antidepressive Agents, Second-Generation
Autonomic Agents
Central Nervous System Agents
Cholinergic Agents
Cholinergic Agonists
Dopamine Agents
Dopamine Uptake Inhibitors
Ganglionic Stimulants
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Neurotransmitter Uptake Inhibitors
Nicotinic Agonists
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Psychotropic Drugs
Therapeutic Uses processed this record on November 20, 2014